Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SAN RAMON, Calif., March 07, 2016 -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the 28th Annual ROTH Conference. The presentation will take place on Monday, March 14, 2016 at 8:00 a.m. PT at the Ritz Carlton Hotel in Laguna Nigel, CA.
The presentation will be webcast and available on the Investors section of the Company's website at http://investors.galenabiopharma.com/events.cfm.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 breast cancer clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancer and in a Phase 1b given sequentially with GALE-302. For more information, visit www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact: Remy Bernarda SVP, Investor Relations & Corporate Communications (925) 498-7709 [email protected]
